Abstract

In recent decades, abundant methods for targeted tumor cell immunotherapy have been developed. It was recently discovered that excellent curative effects observed in hematological tumors cannot be achieved in solid tumors, as serious side effects will occur. These are all derived from engineered adaptive immune cells, the use of which will bring limitations. γδT cells have a unique ability to respond to a variety of tumor cells while linking innate immunity and adaptive immunity, and thus, they are an ideal source of therapeutic allogeneic cells. This review introduces strategies that can optimize the clinical application of γδT cells to provide novel ideas for adoptive immunotherapy in the future.

Highlights

  • ΓδT cells are primarily distributed in subcutaneous tissue, intestinal mucosa, the respiratory tract, and the urogenital canal [1]

  • This review introduces strategies that can optimize the clinical application of γδT cells to provide novel ideas for adoptive immunotherapy in the future

  • There are no serious adverse reactions related to γδT cells therapy, which has satisfactory therapeutic effects on hematologic tumors and solid tumors. γδT cells can distinguish tumor cells from healthy cells by sensing the stress signals expressed by tumor cells

Read more

Summary

Exploration of Immunology

Cite this article: Zhang X, Xu Y, Chen H, Zhang J, He W. ΓδT cells: alternative treasure in antitumor immunity.

Introduction
Methods of expanding γδT cells ex vivo for adoptive therapy
Agents with the potentials to stimulate γδT cells in vivo
Autologous transplantation
Allogeneic transplantation
Genetic engineering γδT cells γδTCR transfer into αβT cells
NKT TCR transfer into γδT cells
CAR T engineered strategies
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call